Skip Navigation

European Heart Journal 1993 14(4):540-545;
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by JESPERSEN, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JESPERSEN, C. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction

C. M. JESPERSEN and THE DANISH Srur GROUP ON VERAPAMIL IN MYOCARDIAL INFARCTION*

The Second Department of Medicine, Municipal Hospital Copenhagen, Denmark

Received 12 May 1992; revised 10 June 1992; .

Correspondence: C M. Jespersen, Østerbrogade 82, DK-2 100, Copenhagen Ø. Denmark.

Abstract

In the Danish Verapamil Infarction Trial II (DAVIT II) intervention with verapamil significantly decreased the first major event rate (i.e. reinfarction or death) in patients recovering from acute myocardial infarction. As calcium channel antagonists might have a detrimental effect in patients with heart failure, the effect of verapamil on major events in patients with and without impaired left ventricular function was analysed.

Eight hundred and seventy-eight patients were randomized to verapamil 120 mg t.i.d. and 897 to placebo. Patients were followed up to 18 months. The endpoint was the first major event while on trial medication. In patients treated for heart failure during the acute phase of myocardial infarction, the lowest 18-month event rate was seen in the verapamil group (21.2 vs 22.2%) (absolute numbers: events/patients verapamil 47/291; placebo 60/323) (ns). Similarly, in patients treated with diuretics at randomization, the lowest 18-month event rate was seen in those randomizedto verapamil (22.4 vs 24.3% (absolute numbers: events/patients verapamil 57/349; placebo 76/375) (ns). When patients were subdivided according to New York Heart Association functional classes, verapamil reduced the event rate in all classes, but none of these differences was statistically significant. In patients without heart failure during the acute phase and in patients without diuretic treatment at randomization, treatment with verapamil caused a significant reduction in major events (hazard ratio (95% confidence limits): 0.66 (0.47, 0.92):0.66 (0.45, 0.96) respectively).

Long-term treatment with verapamil after acute myocardial infarction caused a significant reduction in major events. The beneficial effect was most pronounced in patients without impaired cardiac function, and decreased with increasing impairment of left ventricular function, but never reached a detrimental level in patients with mild to moderate ischaemic heart failure.

Key Words: Myocardial infarction • prognosis • heart failure • verapamil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
D. R. Abernethy and J. B. Schwartz
Calcium-Antagonist Drugs
N. Engl. J. Med., November 4, 1999; 341(19): 1447 - 1457.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.